Maryalice Stetler‐Stevenson

National Cancer Institute — United States

Medicine · Health Sciences

75h-index29.0kcitations383works33.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(146), Lymphoma Diagnosis and Treatment(131), CAR-T cell therapy research(66), Multiple Myeloma Research and Treatments(57), Immunodeficiency and Autoimmune Disorders(44)

Publications383 total

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Blood·2025· 2 citedOpen Access
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma
Blood·2024· 91 citedOpen Access
Standardization of flow cytometric detection of antigen expression
Cytometry Part B Clinical Cytometry·2024· 7 citedOpen Access
Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial
Blood·2023· 5 cited
Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
2023Open Access
Supplementary Figures Legends from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
2023Open Access
Data from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Conflict of Interest Form from Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
2023Open Access
Supplementary figure 1 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023Open Access
Supplementary figure 4 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023Open Access
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
2023Open Access
Data from Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
2023Open Access
Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
2023Open Access
Data from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
2023Open Access
Supplementary figure 1 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023Open Access
Data from Disruption of <i>in vivo</i> Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
2023Open Access
Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
2023Open Access
Supplementary figure 2 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023Open Access
Kaplan-Meier analysis of progression free survival of all patients with ATL who received alemtuzumab therapy from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
2023Open Access
Supplementary Figs and Tables from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Constance M. Yuan(21), Nirali N. Shah(12), Irina Marić(12), Seth M. Steinberg(11), Wyndham H. Wilson(11), Terry J. Fry(10), Robert J. Kreitman(9), Mark Raffeld(8), Ira Pastan(8), Bonnie Yates(7), Adrian Wiestner(7), Elaine S. Jaffe(7), James N. Kochenderfer(6), Steven A. Feldman(6), Haneen Shalabi(6), David F. Stroncek(6), Gerald E. Marti(6), David J. FitzGerald(6), Mohammed Farooqui(6), Janet Valdez(6)